PAYS - Paysign Non-GAAP EBITDA of $0.02 revenue of $8.8M

Paysign press release (NASDAQ:PAYS): Q4 Non-GAAP EBITDA of $0.02. Revenue of $8.8M (+21.4% Y/Y). Shares -8%. Outlook: "For the full year 2022, we expect total revenue to be in the range of $35.25 million to $38.35 million, reflecting growth of 20% to 30%, with plasma making up approximately 90% of total revenue. Pharma revenue is expected to be relatively flat year over year as the loss of programs and settlement income in 2021 are offset with new pharma copay programs." The company expects adjusted EBITDA to be at least double to $4.0 million over 2021’s adjusted EBITDA of $2.0 million. Full year gross profit margins are expected to be approximately 50.0% to 52.5%, with Q1 2022 gross profit margin expected to be approximately 60% before returning to a more normalized gross profit margin experienced in 2021.

For further details see:

Paysign Non-GAAP EBITDA of $0.02, revenue of $8.8M